bioRxivCancer BiologyPreprint
BH3 Profiling Identifies Selective BCL-2 Dependence of Adult Early T-cell Progenitor (ETP) Subtype of Acute Lymphoblastic Leukemia (ALL) Patients
E. A. Olesinski, K. S. Bhatia, J. S. Garica, N. Jain, A. Letai, M. Konopleva, S. Bhatt
Abstract
Early T-cell precursor (ETP) acute lymphoblastic leukemia (T-ALL) is a high-risk subtype of T-ALL and is associated with poor survival outcomes with chemotherapy. We previously showed that maturation stage of thymocytes distinguishes pro-survival dependencies of pediatric ETP-ALL (BCL-2 dependent) from non-ETP-ALL (BCL-XL dependent). Comparable data in adults are lacking. Our present study focuses on characterizing functional dependencies of adult ETP-ALL and T-ALL on BCL-2 family proteins. Using BH3 profiling on primary tumors, we report that similar to pediatric ALL, adult ETP-ALL is primarily dependent on BCL-2; however, unlike pediatric ALL, adult non-ETP-ALL is co-dependent on both BCL-2 and BCL-XL for survival. By measuring direct mitochondrial permeabilization and cell viability assays, we validated that BH3 profiling predicted on-target cytotoxicity of venetoclax in adult ETP-ALL and navitoclax plus venetoclax in adult T-ALL. These findings provide pre-clinical evidence for venetoclax and navitoclax as potentially efficacious combination therapy for adults with T-ALL. Statement of SignificanceAdults with relapsed T-ALL have poor prognosis and represent an unmet need for novel treatments. We report that adult ETP-ALL is dependent on BCL-2 for survival, similar to pediatric ETP-ALL. However, adult non-ETP-ALL is heterogeneously dependent on both BCL-2 and BCL-XL. We characterize key dependencies on BCL-2 family proteins to direct BH3 mimetics therapy in T-ALL patients.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Early cytokine-driven adaptation of survival pathways in lymphoid cells during targeted therapies
M.-X. Luo, T. Tan, … D. H. Gray·bioRxiv·Mar 4, 2024
- Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition
A. Garcia-Gimenez, J. E. Ditcham, … S. E. Richardson·bioRxiv·Oct 2, 2023
- Intracellular BH3 profiling reveals shifts in anti-apoptotic dependency in B-cell maturation and activation
M. A. Luftig, J. Dai·bioRxiv·Jun 9, 2017
- Various Cell Types in the Bone Marrow sustain Primary B-Cell Precursor Acute Lymphoblastic Leukemia
M. W. E. Smeets, C. van de Ven, … M. L. den Boer·bioRxiv·May 25, 2023
- Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy
V.S.S. Abhinav Ayyadevara, Shikha Gaur, … Christian Hurtz·bioRxiv·Jul 8, 2025
- Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expression
S. P. Rinella, H. C. Bell, … C. M. Capitini·bioRxiv·Jun 7, 2023